cabozantinib,atezolizumab
exelixis,roche
['lcsm,(-blcsm)', 'sclc', 'nsclc', 'biomarker']
promising data for cabo+atezo. no biomarker is available to determine who benefits most from anti-angiogenesis in #nsclc #asco22 #lcsm 
#HemeOnc @LombardiCancer | @EmoryDeptofMed @GradyHealth @tulanemedicine alum | Interests #MedEd #clinicaltrials #disparities #lcsm ????|??mom | she/her/hers??